Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of Single Rising Oral Doses of Linagliptin (BI 1356 BS) in Healthy Males
NCT02173665Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2004
- Primary completion
- Dec 2004
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of linagliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of patients with adverse events up to 30 days, Number of patients with abnormal findings in physical examination and 4 more. Started Oct 2004; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02173665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02173665.